{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.6","upperLimit":"6.5","value":"5.7"},{"groupId":"OG001","lowerLimit":"3.2","upperLimit":"4.5","value":"3.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"135"}],"units":"Participants"}],"description":"Time to PSA progression is defined as the time from randomization to the date that a ≥ 25% increase and absolute increase of ≥ 2 ng/mL above the nadir (or baseline value for participants who did not have a decline in PSA) in PSA was measured. The increase must be confirmed by a second consecutive assessment conducted at least 3 weeks later.","dispersionType":"95% Confidence Interval","groups":[{"description":"Oral rucaparib (monotherapy).\n\nRucaparib: Rucaparib will be administered daily.","id":"OG000","title":"Rucaparib"},{"description":"Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).\n\nAbiraterone acetate or Enzalutamide or Docetaxel: Abiraterone acetate and enzalutamide will be administered daily.\n\nDocetaxel will be administered every 3 weeks.","id":"OG001","title":"Abiraterone Acetate or Enzalutamide or Docetaxel"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all randomized participants (participants with BRCA mutated mCRPC and participants with ATM mutated mCRPC).","reportingStatus":"POSTED","timeFrame":"From enrollment to primary completion of study (up to approximately 5 years)","title":"Time to Prostate Specific Antigen (PSA) Progression in Participants With a BRCA or ATM Alteration Combined","type":"SECONDARY","unitOfMeasure":"months"}